NYSE:NVTA - InVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVTA stock has decreased by 11.1% and is now trading at $14.09. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Wednesday, February, 19th. The medical research company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The medical research company had revenue of $66.30 million for the quarter, compared to analyst estimates of $66.62 million. InVitae had a negative return on equity of 58.73% and a negative net margin of 111.60%. The company's revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.40) EPS. View InVitae's earnings history.

5 Wall Street analysts have issued 1 year target prices for InVitae's stock. Their forecasts range from $28.00 to $34.00. On average, they anticipate InVitae's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 120.0% from the stock's current price. View analysts' price targets for InVitae.

News coverage about NVTA stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. InVitae earned a news impact score of -4.0 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutInVitae.

InVitae saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 22,133,500 shares, an increase of 7.4% from the February 27th total of 20,600,000 shares. Based on an average daily trading volume, of 2,880,000 shares, the days-to-cover ratio is presently 7.7 days. Currently, 23.5% of the company's shares are short sold. View InVitae's Current Options Chain.

Some companies that are related to InVitae include ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Centogene (CNTG), Fulgent Genetics (FLGT), Personalis (PSNL), DermTech (DMTK), Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Psychemedics (PMD) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Twilio (TWLO), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Netflix (NFLX).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.89%), Nikko Asset Management Americas Inc. (10.42%), Sumitomo Mitsui Trust Holdings Inc. (10.42%), State Street Corp (6.33%), Alliancebernstein L.P. (3.79%) and Casdin Capital LLC (3.77%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Perceptive Advisors LLC, Perceptive Advisors LLC, Macquarie Group Ltd., Macquarie Group Ltd., UBS Group AG, Casdin Capital LLC, and First Trust Advisors LP. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida. View insider buying and selling activity for InVitae.

NVTA stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., ARK Investment Management LLC, State Street Corp, Norges Bank, Victory Capital Management Inc., Victory Capital Management Inc., and Farallon Capital Management LLC. View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $14.09.

InVitae has a market capitalization of $1.39 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe. View additional information about InVitae.

The official website for InVitae is http://www.invitae.com/.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]